NCT03125577TerminatedPhase 1/2
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
- Status (registry)
- Terminated
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 19 Apr 2017
- Start date
- 1 Aug 2025
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- NCT number
- NCT03125577
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- under systemic steroid treatment within a week of the treatment.
- prior failed CAR-T treatment.
Other illness
- accompanied with other active diseases, the treatment is difficult to assess patient response.
- bacteria, fungus, or virus infection, unable to control.
- living with HIV.
- active HBV and HCV infection.
Other
- pregnant and nursing mothers.
Who the study is looking for
- age older than 6 months.
- malignant B cell surface expression of CD19/CD20/CD22/CD30/CD38/CD70/CD123 molecules.
- the KPS score over 80 points, and survival time is more than 1 month.
- greater than Hgb 80 g/L.
- no contraindications to blood cell collection.
Age in the registry: 6 months to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.